Patents by Inventor Aarron T. Willingham
Aarron T. Willingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
Patent number: 11932854Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: GrantFiled: October 25, 2021Date of Patent: March 19, 2024Assignee: Sirna Therapeutics, Inc.Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham -
Publication number: 20230348904Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: ApplicationFiled: November 10, 2022Publication date: November 2, 2023Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
-
Patent number: 11530407Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: GrantFiled: February 18, 2020Date of Patent: December 20, 2022Assignee: Sirna Therapeutics, Inc.Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
-
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
Publication number: 20220195433Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (MAO against target gene expression.Type: ApplicationFiled: October 25, 2021Publication date: June 23, 2022Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham -
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
Patent number: 11193126Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: GrantFiled: April 6, 2018Date of Patent: December 7, 2021Assignee: SIRNA THERAPEUTICS, INC.Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham -
Publication number: 20200392499Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: ApplicationFiled: February 18, 2020Publication date: December 17, 2020Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
-
Patent number: 10689648Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: GrantFiled: August 23, 2017Date of Patent: June 23, 2020Assignee: SIRNA THERAPEUTICS, INC.Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
-
Patent number: 10584335Abstract: The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: GrantFiled: November 10, 2017Date of Patent: March 10, 2020Assignee: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
Publication number: 20180362977Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: ApplicationFiled: April 6, 2018Publication date: December 20, 2018Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham -
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
Patent number: 9970005Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: GrantFiled: December 30, 2015Date of Patent: May 15, 2018Assignee: SIRNA THERAPEUTICS, INC.Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham -
Publication number: 20180105812Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: ApplicationFiled: August 23, 2017Publication date: April 19, 2018Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
-
Publication number: 20180080024Abstract: The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: ApplicationFiled: November 10, 2017Publication date: March 22, 2018Applicant: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
Patent number: 9845466Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: GrantFiled: December 14, 2015Date of Patent: December 19, 2017Assignee: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
Publication number: 20160264964Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: ApplicationFiled: December 30, 2015Publication date: September 15, 2016Applicant: SIRNA THERAPEUTICS, INC.Inventors: Mark Cancilla, James John Cunningham, Michael William Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham -
Publication number: 20160222381Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: ApplicationFiled: December 14, 2015Publication date: August 4, 2016Applicant: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
Publication number: 20150299696Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: ApplicationFiled: April 26, 2013Publication date: October 22, 2015Applicant: Sirna Therapeutics, Inc.Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
-
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
Publication number: 20130217756Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.Type: ApplicationFiled: October 25, 2011Publication date: August 22, 2013Applicant: MERCK SHARP & DOHME CORP.Inventors: Mark Cancilla, James John Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham